Literature DB >> 34939094

Sweet impersonators: Molecular mimicry of host glycans by bacteria.

Hanna de Jong1,2, Marc M S M Wösten2, Tom Wennekes1.   

Abstract

All bacteria display surface-exposed glycans that can play an important role in their interaction with the host and in select cases mimic the glycans found on host cells, an event called molecular or glycan mimicry. In this review, we highlight the key bacteria that display human glycan mimicry and provide an overview of the involved glycan structures. We also discuss the general trends and outstanding questions associated with human glycan mimicry by bacteria. Finally, we provide an overview of several techniques that have emerged from the discipline of chemical glycobiology, which can aid in the study of the composition, variability, interaction and functional role of these mimicking glycans.
© The Author(s) 2021. Published by Oxford University Press.

Entities:  

Keywords:  bacteria; carbohydrates; chemical biology; glycans; molecular mimicry

Mesh:

Substances:

Year:  2022        PMID: 34939094      PMCID: PMC8881735          DOI: 10.1093/glycob/cwab104

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


Introduction

Bacterial glycans play an important role in host–microbe interactions (Poole et al. 2018). Glycans at the bacterial cell surface are often the first molecules to interact with the environment and can mimic glycan structures of the host. The existence of identical molecular structures on the host and a microbe is referred to as molecular or glycan mimicry (Damian 1964). Bacteria may exploit glycan mimics to hijack host biology to establish infection, but the glycan mimicry may also inadvertently induce abnormal immune responses causing serious auto-immune pathology. Bacterial surface glycans that have been found to display glycan mimicry with host glycan structures include capsular polysaccharides (CPS) and glycolipids, such as lipopolysaccharide (LPS) and lipooligosaccharides (LOS). These bacterial surface glycans mimic certain classes of eukaryotic glycans for which an overview is presented in Figure 1. The bacteria that will be discussed in this review are grouped per class of eukaryotic glycans they are mimicking. A detailed overview of the bacterial glycan structures that display glycan mimicry are depicted in Supplementary Table SI.
Fig. 1

Bacterial glycans can mimic the glycans of the (human) host. Here, the targets of glycan mimicry are grouped for several human glycan types. Bacterial glycans that resemble these and are thus molecular mimics can be found in Supplementary Table SI.

Bacterial glycans can mimic the glycans of the (human) host. Here, the targets of glycan mimicry are grouped for several human glycan types. Bacterial glycans that resemble these and are thus molecular mimics can be found in Supplementary Table SI. The concept of bacterial glycan mimicry and its effects on host immunity has been subject of a few excellent reviews (Mandrell and Apicella 1993; Moran et al. 1996). Here, we will focus on an updated discussion of research into the glycan structures and interacting proteins involved in bacterial host glycan mimicry and its impact on host biology. We have selected 11 bacterial species that display glycan mimicry. First, we will discuss the bacterial glycan structures involved [using a graphical notation according to the current symbol nomenclature (Varki et al. 2015), Supplementary Table SI], their interaction with host receptors (see Figure 2 for an overview) and their role in bacterial pathogenesis. In a second part of the review, we will highlight the potential of recent advances in the field of chemical glycobiology and make a case for their use in future study of bacterial glycan mimicry. Of note, microbe-host mimicry is not limited to glycans and also not all bacterial glycans on microbes that interact with their host are involved in mimicry. However, discussion of other forms of molecular mimicry (e.g., protein mimicry) (Carolin 2019), microbial glycan interactions (Poole et al. 2018) and the nature of unique microbial glycans (Dube et al. 2011; Tra and Dube 2014; Imperiali 2019) is beyond the scope of the current review.
Fig. 2

Interactions between the terminal surface glycan structures of mimicking bacteria and the host’s glycan binding proteins or glycans. The bacteria are indicated by the following letters: (A) N. meningitidis, (B) Group B streptococcus, (C) N. gonorrhoeae, (D) C. jejuni, (E) H. pylori, (F) E. coli and (G) Group A streptococcus.

Interactions between the terminal surface glycan structures of mimicking bacteria and the host’s glycan binding proteins or glycans. The bacteria are indicated by the following letters: (A) N. meningitidis, (B) Group B streptococcus, (C) N. gonorrhoeae, (D) C. jejuni, (E) H. pylori, (F) E. coli and (G) Group A streptococcus.

Bacterial pathogens that display glycan mimicry

Glycosphingolipids

Campylobacter jejuni

One of the most well-studied forms of glycan mimicry involves the bacterial surface glycans of the food-borne pathogen Campylobacter jejuni. Infection by C. jejuni is a common cause of human gastroenteritis and in rare cases can lead to Guillain–Barré syndrome (GBS). In case of GBS, the immune system produces antibodies against the infecting microbe’s glycans that cross-react with similar glycan structures on the host’s nerves (Van Den Berg et al. 2014). GBS can cause acute flaccid paralysis and is classified in different subtypes based on further clinical features (Jasti et al. 2016). Although infections from many different bacteria and viruses could potentially result in GBS (Jasti et al. 2016), C. jejuni is the most frequent preceding infection, especially for the GBS subtypes, acute motor axonal neuropathy and Miller Fisher syndrome (MFS) (Yu et al. 2006; Jasti et al. 2016). Campylobacter jejuni infections are frequent, but only an estimated 1 per 1000 infections results in GBS, which suggests that additional factors play a role in developing GBS (Van Den Berg et al. 2014; Jasti et al. 2016). For C. jejuni, it is well documented that some forms of LOS mimic the gangliosides found on nerves (Moran and Prendergast 2001). Cross-reactive antibodies against different LOS epitopes and gangliosides can be found in patient sera (Prendergast and Moran 2000). In addition, the link between the glycan mimicry of gangliosides and the development of GBS was demonstrated in rabbits (Yuki et al. 2004). The animals were administered GM1-like LOS from a clinical isolate, upon which they developed GBS (Yuki et al. 2004). Campylobacter coli and Brucella melitensis might also have GM1-like structures, because they reacted with an anti-ganglioside antibody (Yu et al. 2006), but it remains unknown whether they can cause GBS (Van Belkum et al. 2009). Although the evidence for a link between glycan mimicry and onset of GBS is strong, it also does not appear to be a prerequisite. For instance, Godschalk et al. (2007) used capillary electrophoresis MS to determine the LOS of C. jejuni strains from patients with Enteritis, GBS and MFS. Although a correlation was found between C. jejuni strains that had mimicking LOS and the diseases GBS and MFS, there were also C. jejuni strains that lacked this type of LOS and did give rise to disease (Godschalk et al. 2007). This suggests that other still unknown factors might play a role in developingGBS. Variants of C. jejuni LOS can bind to several host receptors and although less well studied, also to host glycans (Figure 2) (Day et al. 2015). The Siglec 7 receptor, which occurs on monocyte-derived macrophages, Natural Killer and dendritic cells, is bound by strains associated with GBS and MFS through disialylated LOS and not monosialylated LOS (Avril et al. 2006; Heikema, Jacobs, et al. 2013). LOS that contains a terminal GalNAc can bind to the Macrophage Galactose-type lectin (MGL, CLEC10A and CD301) on immature dendritic cells (van Sorge et al. 2009). LOS structures mimicking Gd1a, GM1b and GM3 gangliosides show binding to both murine (Heikema et al. 2010) and human (Heikema, Koning, et al. 2013) sialoadhesin (Sn, Siglec-1 and CD169) that is dependent on terminal α2,3-linked N-acetylneuraminic acid (α2,3-Neu5Ac). The binding of LOS to Sn leads to increased uptake by the macrophages and increased IL-6 production but does not facilitate bacterial survival as lysosomal degradation still occurs. The exact role of Sn binding remains unclear, but Sn-mediated LOS ingestion by antigen presenting cells might facilitate the production of auto-antibodies (Heikema, Koning, et al. 2013). The key role of the sialic acid family, mainly in the form of Neu5Ac, in glycan mimicry by C. jejuni LOS has also been confirmed by genetic studies. For example, mutations of either heptosyltransferase, which leads to truncated LOS (Perera et al. 2007), or Neu5Ac synthetase (Xiang et al. 2006) both abolish LOS sialylation and mimicry. The sialyltransferase CstII is responsible for the sialyation of LOS and can create either α2,3- or both α2,3- and α2,8-linkages, depending on only a single point mutation (Gilbert et al. 2002; Godschalk et al. 2007). In vitro studies of C. jejuni with sialylated LOS show that it is more invasive yet less adherent (Louwen et al. 2008). Additionally, sialylated LOS facilitates translocation across Caco-2 cells, yet intracellular survival depends on the number of translocated bacteria and not on LOS structure (Louwen et al. 2012). Most studies on LOS sialylation are in vitro, so the exact in vivo role remains to be further elucidated. However, a patient study from Finland indicated that LOS sialylation might only have a limited contribution to in vivo invasiveness (Ellström et al. 2014). Only 23% of the C. jejuni isolates had the genetic potential to sialylate the LOS (Ellström et al. 2014). Besides the genetic potential for mimicry by C. jejuni, the exact LOS composition in a culture is also dependent on growth conditions. For example, the model strain C. jejuni 11 168 produces LOS with 90% of glycan structures mimicking GM1 if grown at 37°C, which drops to 50% if grown at 42°C (Day et al. 2012). Day et al. (2012) suggest that the heterogeneity of LOS could contribute to population fitness and hypothesized that the different LOS structures form multiple targets for auto-antibodies.

Moraxella catarrhalis

Moraxella catarrhalis is a nonmotile gram-negative pathogenic bacterium with an affinity for the human upper respiratory system. The LOS of serotype A, B and C was shown to have a common Gal-Gal-Glc motive, which can also be found on human glycolipids (Masoud et al. 1994; Holme et al. 1999; Schwingel et al. 2009). The interactions of the LOS with host biology remain to be studied. The glycan mimicry by this bacterium might aid in host colonization and invasion (Holme et al. 1999).

Blood group antigens

Helicobacter pylori

Helicobacter pylori is a gram-negative, microaerophilic, helically shaped bacterium. It is a gastric pathogen that persists for a lifetime in most human’s stomach (Appelmelk et al. 2000) and can lead to a variety of diseases, such as gastric and duodenal ulcers, chronic gastritis and mucosa-associated lymphoid tissue (Chmiela and Gonciarz 2017). This persistent colonization is associated with glycan mimicry by the O-antigen of H. pylori’s LPS of Lewis blood group antigens (Moran and Prendergast 2001; Bergman et al. 2006). A study that investigated the LPS composition of eight Helicobacter strains with reactivity toward antibodies directed against Lewis antigens found only H. pylori and H. mustelae displayed glycan mimicry, of which the latter is a pathogen that can be found in ferrets (Hynes et al. 2004). In an effort to understand the role of glycan mimicry in auto-immunity, Appelmelk et al. (1996) studied seven H. pylori strains for mimicry with antibodies against Lewis antigens and found cross reactivity between LPS and gastric tissue. The glycan structure of H. pylori LPS is important for invasiveness (Leker et al. 2017), colonization (Logan et al. 2000) and antigenicity (Chmiela et al. 2014); details on the biosynthesis of LPS with Lewis antigens have been previously described (Li et al. 2016, 2017). Helicobacter pylori with truncated LPS, which lacks the O-antigen, colonized less compared with wildtype (Logan et al. 2000). Comparison of the glycan composition of two H. pylori strains with different virulence found that they differed in the monosaccharides rhamnose and mannose, yet the significance of this for invasiveness remains unclear (Leker et al. 2017). In relation to antigenicity, one study compared a weakly and highly antigenic form of LPS and the two LPS structures only differed in one GlcNAc residue (Chmiela et al. 2014), highlighting that a minor change in glycan structure can have direct impact on immunogenicity. Helicobacter pylori might persist in the host by balancing the population of T-helper-1 and -2-cells through phase variation and expression of Lewis antigens (Bergman et al. 2006). This balance might be achieved via Lewis x and Lewis y that bind to DC-SIGN (Figure 2), which causes a down-regulation in T-helper-1-cells (Bergman et al. 2006; Li et al. 2016). Besides their binding to DC-SIGN, Lewis antigens bind to several other receptors (Figure 2). Lewis x binds to Galectin-3 and is thought to contribute to adhesion (Li et al. 2016). Helicobacter pylori O-antigens with a lower degree of fucosylation preferentially bind to surfactant protein D and this is dependent on the phase-variable expression of the bacterial fucosyltransferase (Khamri et al. 2005; Chmiela et al. 2014; Li et al. 2016). For a more detailed discussion about the function of glycan mimicry for H. pylori, the reader is referred to a perspective by Bergman et al. (2006).

Polysialic acid

Escherichia coli

Escherichia coli is a gram-negative, facultative anaerobic, bacterium that is commonly found in the lower intestine. Its O-antigen and capsule can display glycan mimicry. The O-antigen is composed of 10–25 repeating units of two to seven monosaccharides (Stenutz and Weintraub 2006). Serotypes O86, O90, O127 and O128 are presumed to be glycan mimicking due to their resemblance to blood group antigens (Stenutz and Weintraub 2006). For more details, we refer to a comprehensive overview of O-antigens of E. coli (Stenutz and Weintraub 2006). The capsule of E. coli K1 and K92 consists of polysialic acid, which is either α2,8- or both α2,8- and α2,9-linked, respectively (Suerbaum et al. 1994), and mimics the polysialic acid found on neural cell adhesion molecules (Steenbergen et al. 1992). Contrary to vertebrates, where polysialylation is found on the nonreducing termini of sialylated N- and O-linked glycans of certain glycoproteins, bacterial polysialic acid structures are covalently linked to an oligo-KDO that is anchored to the plasma membrane (Lizak et al. 2017). The capsule of E. coli K1 was shown to bind both inhibitory Siglec 11 and activating Siglec 16 (Figure 2), which give opposite signals to the immune system (Schwarz et al. 2017). In addition to Siglec binding, the polysialic acid capsule possibly also recruits factor H, as described for Neisseria meningitidis (Figure 2) (Suerbaum et al. 1994).

Neisseria meningitidis serogroup B

Neisseria meningitidis is a gram-negative bacterium that can cause meningitis and sepsis. Its serogroup B strain has a polysialic acid capsule that mimics the polysialic acid that can be found on neural cell adhesion molecules, similar to E. coli (Steenbergen et al. 1992). Neisseria meningitidis serogroup C also has a polysialic acid capsule but is α2,9-linked instead of α2,8-linked like the capsule of serogroup B. Although this serogroup C, and the serogroups W-135 and Y contain Neu5Ac, these have not been described as involved in glycan mimicry. For a more detailed discussion about the glycan structures of Neisseria, the reader is referred to two excellent reviews (Mandrell and Apicella 1993; Mubaiwa, Semchenko, et al. 2017). A possible function of the glycan mimicry by N. meningitidis serogroup B’s polysialic acid capsule could be immune evasion through the possible recruitment of factor H (Figure 2), which suppresses the complement system, conferring serum-resistance (Jarvis and Vedros 1987). If there is less sialylation of the capsule, there is more C3 deposition on the bacterial cell surface (Jarvis and Vedros 1987). The binding of C3 on the cell surface is the first step in the complement pathway to form the membrane-attack complex that eventually can lead to cell death (Doorduijn et al. 2016). The deposited C3 can be removed by factor H, which is usually responsible for recognizing “self,” and it has been hypothesized that Neu5Ac could attract factor H (Jarvis and Vedros 1987).

Human glycoproteins

Neisseria meningitidis

The LOS of N. meningitidis contains a terminal structure, lacto-N-neotetraose, that is also found on human glycoproteins and glycosphingolipids (Tsai et al. 1998). Sialyltransferases from N. meningitidis sialylate its LOS, often with an α2,3-linkage, except for immunotype L1 in which its α2,6-linked Neu5Ac (Tsai et al. 1998, 2002). This Sialylated LOS has been shown to bind to Siglecs Sn or 5 (Figure 2) (Jones et al. 2003); 3-Sialyllactosamine or 3-siallylactose that is coupled to polyacrylamide probes has been shown to bind even more Siglecs. The fact that meningococcal LOS only binds two but has identical terminal structures shows that the underlying LOS glycan structure probably also plays a role in this. Of note is that Siglecs Sn or 5 do have a relaxed ligand specificity and can bind sialylated galactose connected through either an α2,3- α2,6- or α2,8- linkage (Jones et al. 2003). It has been hypothesized that binding of LOS to Siglecs could lead to the release of inhibitory signals or to uptake of the bacteria with a trojan horse-like effect (Jones et al. 2003). Truncated meningococcal LOS that instead contains a terminal GlcNAc (lgtB mutant) has been found to bind DC-SIGN, another important lectin for the immune system (Steeghs et al. 2006). However, because the lgtB mutant is not phase variable, it probably does not have an in vivo contribution to infection (Johswich 2017). Interestingly, a glycan array study identified 31 interactions between LOS of immunotype L3 and L8 and host glycans, including the high-affinity binding to the Thomsen–Friedenreich antigen (Mubaiwa, Hartley-Tassell, et al. 2017). The downstream effects of these glycan–glycan interactions on meningococcal infection remain to be investigated. In general, the glycan mimicry by meningococcal LOS is thought to be a form of immune evasion (Mandrell and Apicella 1993; Tsai et al. 1998; Mubaiwa, Semchenko, et al. 2017). LOS sialylation could for instance prevent the binding of antibodies of the classical pathway or inhibit parts of the complement pathway (Lewis et al. 2012). The mimicking LOS has many interactions with the host cells that might aid in immune evasion, but the detailed mechanism of immune evasion is not clearyet.

Neisseria gonorrhoeae

Neisseria gonorrhoeae is a gram-negative, diplococci bacteria that causes the sexually transmitted gonorrhea infection. Its LOS, similar to N. meningitidis, contains terminal lacto-N-neotetraose that mimics human glycoproteins and glycosphingolipids (Tong et al. 2002). Gonococcal LOS is phase-variable and can be sialylated, typically with an α2,3-linkage except for the PK LOS which contains a α2,6-linkage (Tong et al. 2002; Gulati et al. 2015). Phase-variable gonococcal LOS has multiple interactions with host cells (Figure 2) and can bind to C-type lectins MGL and DC-SIGN in case of a terminal N-acetylglucosamine or N-acetylgalactosamine, respectively (Van Vliet et al. 2009). Binding to DC-SIGN results in increased IL-10 production and binding to MGL skews the population to T helper 2 cells, the latter could be a form of immune evasion (Van Vliet et al. 2009). Sialylation of LOS plays an important factor in the interaction of N. gonorrhoeae with its host. Upon invasion, only bacteria with low levels of sialylated LOS invade the host epithelial cells (van Putten 1993). In absence of sialylation, the exposed terminal lactosamine residues of the LOS bind to the asialoglycoprotein receptor (ASGP-R) (Harvey et al. 2001) that induces clathrin-dependent receptor-mediated endocytosis, thus facilitating invasion. Once inside the host cell, the bacteria can sialylate themselves by scavenging the host’s CMP-Neu5Ac, resulting in serum resistance (van Putten 1993). Several reasons have been postulated for why sialylation of gonococcal LOS contributes to immune evasion, including: recruitment of factor H, shielding of underlying immunogenic structures against antibodies and engagement of human inhibitory Siglecs (Landig et al. 2019). Finally, it is hypothesized that N. gonorrhoeae has evolved to specifically use Neu5Ac to commit to a human host and to avoid innate immunity, as the immune system would be triggered by LOS with N-glycolylneuraminic acid (Neu5Gc) (Landig et al. 2019). Notably, when incorporating different sialic acids on the gonococcal LOS, including Neu5Ac, Neu5Gc, Pseudaminic acid (Pse) and Legionaminic acid (Leg), it was found that both Neu5Ac and NeuGc confer high serum resistance (Gulati et al. 2015).

Nontypeable Haemophilus influenzae

Nontypeable Haemophilus influenzae (NTHi) is a gram-negative, facultatively anaerobic, opportunistic pathogen that can cause otitis media. The LOS of nontypeable H. influenzae is glycan mimicking when it contains a terminal N-acetyllactosamine, similar to Neisseria spp, or a lactose that is capped with a Neu5Ac (Phillips et al. 1992; Apicella 2012; Day et al. 2015; Kalograiaki et al. 2016). The structure of NTHi375 and RdKW20 LOS have been shown to bind galactose specific lectins through microarray technologies (Kalograiaki et al. 2016, 2018). There has also been a report that NTHi LOS might have a terminal KDO, illustrating LOS heterogeneity (Apicella et al. 2018). The interactions and role of these mimicking LOS in NTHi pathogenesis are not fully understood. Heise et al. (2018) used a probe to study the sialylation of the LOS of NTHi. Combined with a sialyltransferase inhibitor, they showed decreased serum resistance when the LOS was not sialylated and thus a possible function of this in glycan mimicry (Heise et al. 2018). The sialylation of NTHi does not lead to more factor H binding, but to less deposition of C3 on the bacterial surface (Figueira et al. 2007). Sialylated LOS might also mask the underlying glycans and thus prevent the binding of antibodies of the classical complement pathway (Jackson et al. 2019), a similar observation was made for Neu5Gc (Oerlemans et al. 2019). However, as an indication of the complexity of bacterial glycan mimicry in relation to the host immune system, it has also been shown that the uptake by NTHi of nonhuman Neu5Gc from the human diet can lead to the formation of anti-Neu5Gc antibodies that were shown to bind specifically to Neu5Gc-displaying NTHi and not to nonsialylated NTHi (Taylor et al. 2010).

Haemophilus ducreyi

Haemophilus ducreyi is a human pathogen that can cause chancroid. Similar to NTHi, the LOS can contain a terminal N-acetyllactosamine, which can also be sialylated (Melaugh et al. 1994, 1996; Schweda et al. 1994). Haemophilus ducreyi sialylates its LOS, by scavenging Neu5Ac from the environment since it does not have the necessary biosynthetic pathway to produce Neu5Ac (Goon et al. 2003; Wratil et al. 2016). The LOS of H. ducreyi has been shown to contribute to binding of human foreskin fibroblast and keratinocytes, among other components (Alfa and Degagne 1997; Gibson et al. 1997), yet it remains to be investigated whether this interaction depends on glycan mimicry. Although the LOS of H. ducreyi can be sialylated, this does not appear to function as a form of immune evasion, because the strain is virulent regardless of the sialylation (Spinola et al. 2012). Additionally, the bacterium is resistant against serum, so sialylation is not required for the recruitment of factor H. The sialylation of the LOS might have occurred to commit to a human host (Spinola et al. 2012).

Klebsiella pneumoniae

Klebsiella pneumoniae is a gram-negative, nonmotile, facultative anaerobic, rod-shaped bacterium that colonizes the human mucosal surfaces of the oropharynx and gastrointestinal tract. The capsule is an important virulence factor and may contain terminal Neu5Ac, as suggested for K. pneumonia showing the hypermucoviscosity phenotype (Lee et al. 2014), but the capsule structure has not been fully elucidated yet. At first glance, the bacteria seem to engage with inhibitory Siglec 9, but further studies are needed to confirm this binding (Lee et al. 2014). The sialylated capsule of K. pneumonia could prevent complement mediated phagocytosis or might attract complement factor H to deactivate C3 (Doorduijn et al. 2016) and would thus aid in immune evasion.

Group B Streptococcus

Within the genus of Streptococcus, a gram-positive, spherical bacteria, the group B Streptococcus (GBS, Streptococcus agalactiae) can be classified into 10 serotypes that all have a terminal α2,3-Neu5Ac. GBS serotype III dampens the host immune response (Carlin et al. 2009) by binding to Siglec-9 (Figure 2) (Carlin et al. 2007), an inhibitory receptor found on human neutrophils and platelets (Uchiyama et al. 2019). In case of platelets, Neu5Ac binds the inhibitory Siglec-9, which suppresses platelet activation, and is considered responsible for intrinsic resistance against microbial peptides (Uchiyama et al. 2019). Overall, the glycan mimicry of GBS could aid its survival (Carlin et al. 2009; Yamaguchi et al. 2016).

Hyaluronan

Group A Streptococcus

Group A Streptococcus (GAS, Streptococcus pyogenes) is a gram-positive, spherical bacteria that has a capsule containing hyaluranon, a glycan which can also be found in humans as part of the extracellular matrix (Mouw et al. 2014). GAS can bind to the human inhibitory receptor Siglec-9 (Figure 2) (Secundino et al. 2016). Although Siglec-9 is a sialic acid receptor, it was reported that the hyaluranon of GAS can also bind to this receptor. The interaction between Siglec-9 and GAS is specific for hyaluranon and is not observed for glycosaminoglycans such as heparan sulfate and chrondoitin sulfate (Secundino et al. 2016). As Siglec-9 binds both Group A and B Streptococcus (Carlin et al. 2007, 2009), it is involved in glycan mimicry by two bacteria with structurally different glycans that also each have distinct Siglec-9 binding sites (Secundino et al. 2016). The downstream effect of this interaction with inhibitory Siglec-9 and, in general, the effect on pathology by the glycan mimicry of GAS remains to be further studied.

General trends and outstanding questions in bacterial glycan mimicry

The previous sections provided a brief overview of the bacteria, glycans, lectins and interactions involved in glycan mimicry by bacteria. Although these encompass a very diverse set of glycan structures and bacterial species, some general trends can be observed. First, most glycan mimicking bacteria are gram-negative. Second, mostly facultative anaerobe mucosal pathogens display glycan mimicry. Third, Neu5Ac is a recurring monosaccharide involved in glycan mimicry. We will briefly discuss the third trend, because several published hypotheses have attempted to explain this observation. The presence of Neu5Ac in bacterial glycoconjugates stands out and the reason for its occurrence in specific bacterial species has been the subject of much discussion, but the exact reason for its involvement in glycan mimicry by bacteria is unknown. A general hypothesis is that Neu5Ac is displayed by bacteria in glycan mimicry for its prominent terminal position on mammalian glycans and its charge. An associated question is if other terminal sialic acids found on bacteria, such as Pse and Leg, also have a function in glycan mimicry. Another hypothesis for the frequent involvement of Neu5Ac in glycan mimicry is their interaction with Siglecs. Many mimicking bacteria interact with inhibitory Siglecs and can thereby downregulate their host’s immune response (Crocker et al. 2007). In turn, their interaction with inhibitory Siglecs might have led to the evolution of activating Siglecs and perhaps also to the microbial glycan activated intelectins (Wesener et al. 2015; Schwarz et al. 2017). Varki (2006) has postulated that these type of interactions might be tied to the Red Queen effect, an evolutionary race between host and pathogen, which might explain the diversification of glycans. The engagement of Siglecs by bacterial glycans could also play a role in masking the bacteria as “self.” For instance, human Siglecs do not recognize the nonhuman Neu5Gc and this glycan has also not been found on bacteria (Crocker et al. 2007; Varki 2017). This suggests that bacteria have committed to using only Neu5Ac to avoid immune recognition (Padler-Karavani et al. 2008; Ng et al. 2019). These hypotheses and the possible role of sialic acids in glycan mimicry by bacteria are part of an ongoing discussion (Varki 2006, 2017; Varki and Gagneux 2012). Besides the general trends mentioned, there are still many unanswered questions about glycan mimicry by bacteria, see Box 1 for the outstanding questions highlighted by us. A major outstanding question is: what is the function of glycan mimicry? For a few bacteria, their interactions and influence on the host’s immune system are known, with sialylated glycan mimicry playing a prominent role, but an unequivocal conclusion for the existence and function of glycan mimicry cannot yet be made. This and other outstanding questions provide ample opportunities for research. In the final part of the review, we highlight one specific discipline, chemical glycobiology, that we believe that will contribute significantly in studying glycan mimicry by bacteria. What are the minimal glycan structures required by specific bacteria to achieve functional glycan mimicry? Besides Neu5Ac, could other sialic acids such as Pse/Leg play a role in glycan mimicry? (Stenutz and Weintraub 2006; Lewis et al. 2009; Gulati et al. 2015) To what extent does sialic acid O-acetylation (Lewis et al. 2004, 2007; Houliston et al. 2006; Dzieciatkowska et al. 2007) occur on mimicking bacteria and does this O-acetylation affect glycan mimicry and its function? What is the exact location, lifetime and substrate specificity of the native sialyltransferases used by various bacteria to sialylate their outer glycans involved in glycan mimicry? Can human Galectins discriminate between self and nonself glycans, and thus act as a form of immunity? (Stowell et al. 2014; Arthur et al. 2015) Do commensal bacteria also use glycan mimicry to maintain themselves at the host gut microbiota interface which is continuously exposed to our immune system?

Chemical glycobiology techniques to study glycan mimicry

Human glycan mimicry by bacteria is a complex phenomenon that involves many interacting elements and thus needs to be studied with various approaches. Frequently used approaches are biochemistry and genetics (Ausubel 1987; Moran et al. 2009). Techniques from these fields can, for example, demonstrate the cross-reactivity between antibodies of the host and a microorganism or make mutations in glycosyltransferases and glycosidases involved in LPS/LOS biosynthesis to further dissect their function. Chemical glycobiology is a powerful approach that has emerged over the past two decades to study and understand glycans and their function, and carbohydrate-related proteins. The assembly of all glycans, also bacterial, is not template-driven and this poses unique challenges in studying glycobiology (Wen et al. 2018; Zol-Hanlon and Schumann 2020). Glycans are also generally more diverse in structure and often exert their function in a multivalent fashion as heterogeneous mixtures. This structural complexity offers an opportunity for a chemistry-based strategy to unravel the complex mechanisms at play in glycobiology. Indeed, the past two decades has seen the development of many techniques for the study of microbial glycobiology, in addition to the chemical techniques to study other bacterial components such as amino acids, lipids and peptidoglycan (Griffin and Hsieh-Wilson 2016; Zhang et al. 2020). In the following sections, we will highlight several of these chemical glycobiology techniques (Figure 3) and report on their application or speculate on their potential use to study bacterial mimicry of human glycans.
Fig. 3

Chemical glycobiology techniques to study glycan mimicry on bacteria and theirhost.

Chemical glycobiology techniques to study glycan mimicry on bacteria and theirhost.

Metabolic oligosaccharide engineering

Metabolic Oligosaccharide Engineering (MOE) is a technique that uses the cells’ own metabolic salvage pathway to incorporate an externally administered monosaccharide-based probe into glycoconjugates. These monosaccharide-based probes typically contain an unnatural functional group that can be covalently coupled through a click reaction to a reporter group, for example, biotin or a fluorophore, after incorporation into the bacterial glycans. It can serve as a technique to detect the presence of a specific monosaccharide in a complex glycoconjugates (e.g., LPS) in vivo or in vitro. Due to the possibility of attaching artificial groups to the labeled glycan, it can also be used to engineer the target glycoconjugate to investigate its structure–activity relationship or perturb an interaction with an associated lectin. MOE has been performed with glycans that are unique for bacteria (Dube et al. 2011; Tra and Dube 2014), for example, bacillosamine in N-linked glycans of C. jejuni, Legionaminic acid (Leg) in Legionella Pneumophilia (Pons et al. 2014) and C. jejuni (Meng et al. 2021) and Pseudaminic acid (Pse) in C. jejuni, Pseudomonas aeruginosa, Acinetobacter baumannii and Vibrio vulnificus (Liu et al. 2009; Andolina et al. 2018). Two groups of unique bacterial glycans that are especially interesting to study glycan mimicry are: (1) monosaccharides that are frequently found on the core of the LOS, such as KDO and heptose, and (2) nonulosonic acids, such as the previously mentioned Pse and Leg, to dissect the role of these microbial sialic acids further (Tra and Dube 2014; Clark et al. 2016). The extensive monosaccharide “toolbox” with different chemical reporters that has been developed for MOE in mammalian cells can be used to study the role of N-acetylneuraminic acid and other human monosaccharides in glycan mimicry by bacteria (Sminia et al. 2016; Moons et al. 2019). MOE is often performed with monosaccharides that have a chemical reporter, which can reveal the incorporation into a potentially unknown glycoconjugate or the location of the labeled bacteria (see also imaging). A useful way to influence this process is to make use of inhibitors that can perturb the transferase enzymes of the glycan biosynthesis pathway. An illustrative example of such an approach was the study of LOS sialylation by NTHi which used a Neu5Ac probe in combination with a metabolic sialyltransferase inhibitor (Heise et al. 2018). By itself, the development of activity-based probes and (metabolic) inhibitors to perturb, detect and identify the glycosyl hydrolase and transferase enzymes involved in the processing of bacterial glycans is an important emerging research direction toward understanding bacterial glycobiology (Gloster and Vocadlo 2012; Wu et al. 2019; Luijkx et al. 2021). MOE has two main drawbacks. One drawback is that the efficiency of MOE can vary a lot per bacterial species or strain, for instance bacteria can also degrade the probes for growth, which would require optimization per “tool” (Nischan and Kohler 2016). Second, a probe is processed through the bacteria’s metabolic pathway, which leads to incorporation into various types of glycoconjugates with limited control over this. An advantage of MOE is that the technique has been fairly well developed for microbiology and many of the monosaccharide probes and associated chemical reporters are commercially available. MOE provides exciting opportunities to study glycan mimicry and its function and possibly might also provide leads for future glycotherapies (Hudak and Bertozzi 2014; Tra and Dube 2014).

Enzymatic methods

Another approach to glycoengineer and thereby study the composition and function of complex glycoconjugates in a living organism is to make use of enzymes; here, we describe six of these techniques. First, the technique called selective exoenzymatic labeling, also called chemoenzymatic labeling, has been used to track N-glycans, identify human glycoproteins and introduce a large biomolecule (Mbua et al. 2013; Sun et al. 2016; Capicciotti et al. 2017). The technique has mostly been applied to mammalian cells thus far but can be used for glycoengineering of bacteria [unpublished data by our group]. A detailed review of the different enzymes available and their substrate scope has been reported (Lopez Aguilar et al. 2017). A second engineering technique is to remove subclasses of N-glycans on mammalian cells by trimming them with the appropriate glycosidases and insert whole N-glycans with a chemical handle, an oxazoline (Tang et al. 2020). This technique could potentially homogenize the cell surface. This approach could also be used to homogenize the LOS of bacteria, although this would require extensive engineering of the enzymes and glycans involved. A third technique studies the function of glycosyltransferases and their acceptors through bump-and-hole engineering, which employs a complementary set of modified enzymes and substrates that are not naturally present in a cell. Schumann et al. (2020) applied this to N-acetylgalactosaminyl transferases to profile the targets of this family of enzymes. This technique can be used to engineer the cell surface in a targeted way with glycans or clickable groups but also to scan for substrate specificity or labeling without the interference of other native bacterial transferases. Most of the developed enzymatic glycoengineering techniques have only been applied to mammalian cells, but there are a few examples for bacteria. One study screened the substrate promiscuity of several enzymes involved in the biosynthesis of the heptasaccharide on the N-glycans of C. jejuni to introduce azides (Lukose et al. 2015). Attempts to label in vivo failed, because the labeled monosaccharide precursors were not converted to the corresponding nucleotide sugars (Lukose et al. 2015). In another study, the enzymatic synthesis of a glycolipid was developed to incorporate an arabinose onto the cell surface of mycobacterium (Calabretta et al. 2019). This strategy could, for example, also be applied to study the glycolipid portion of the LOS that is involved in mimicry. The LOS of bacteria can also be glycoengineered through genetically introduced transferases (Mally et al. 2013). This approach was applied to engineer the O-antigen of E. coli and Salmonella enterica serovar Typhimurium (Mally et al. 2013). This technique can build a poly LacNAc unit, or a Lewis x motive, on a truncated lipid A core, and therefore, the LOS becomes glycan mimicking.

Imaging

In the past, labeled lectins or antibodies have often been used to indirectly detect and image certain glycans on the cell surface of bacteria. However, a powerful way to study glycan mimicry would be to directly image the actual glycans themselves. The Kasper group applied MOE to fluorescently label and track commensal bacteria in the gut via their cell surface glycans (Geva-Zatorsky et al. 2015). In another study, they labeled multiple glycoconjugates of the cell wall: peptidoglycan, LPS and CPS, with different fluorophores and tracked these bacteria (Hudak et al. 2017). Bacteria involved in glycan mimicry could also be labeled as such and visualized, for example, on their LOS or LPS (Wang et al. 2019; Heesterbeek et al. 2021). Imaging and spatiotemporal tracking of a specific glycan on a commensal or pathogenic bacterium in the presence of a mammalian cell model or even in vivo in an animal model (with for instance near-IR dyes) could provide valuable information about their location and their possible interaction partners.

Interactions

Glycan microarrays are an important technique to study bacterial glycans and their interactions. One approach to study glycan mimicry with microarrays is to investigate the binding of mimicking glycans to lectins of the innate immune system (Stowell et al. 2014). Another approach is to study the binding of unknown bacterial glycans to lectins on a microarray in order to glycophenotype the bacterial glycan coat (Semchenko et al. 2011, 2012; Tytgat and de Vos 2016). The presence of mimicking glycan structures on commensal bacteria might be elucidated with glycophenotyping. For a detailed overview of the application of microarrays to study both bacterial glycans and their interactions, we refer the reader to a recent review (Campanero-Rhodes et al. 2020). In case the interactions between bacterial glycans and receptors are known, it might be possible to manipulate this interaction and steer it to a receptor of choice. In a recent study, Natural Killer cells were modified via MOE with a set of Neu5Ac’s that contained unnatural groups, of which some enhanced the binding to a tumor cell receptor that in turn led to increased tumor lysis (Wang et al. 2020). When studying a specific glycan-receptor interaction, multivalency effects play an important role and can be investigated with defined multimers of the bacterial glycans (Bernardi et al. 2013). In case of glycan mimicry by bacteria, a more fundamental application can be thought of where the binding to different receptors and the effect on the immune system can be studied, for example, the binding of activating or inhibiting Siglecs by N. gonorrhoeae (Landig et al. 2019). A set of molecules containing bio-orthogonal click groups is available to increase binding to certain Siglecs (Büll et al. 2017). In case the in vivo interactions between bacterial glycans and receptors or binding partners are unknown, a photoreactive group, like a diazirine, might be installed on the bacterial glycans to photocrosslink nearby receptors (Nischan and Kohler 2016) and use proteomics to identify these binding partners.

Synthesis and structure elucidation

Progress to make glycans more accessible through automated glycan synthesis, both chemically and enzymatically, will speed up the study of glycobiology (Wen et al. 2018; Li, Yu, et al. 2020). Some examples that are of special interest for glycan mimicry are gangliosides and poly-LacNAc repeats that were synthesized through automated synthesis in combination with enzymes (Li et al. 2019) or the LOS of C. jejuni that was synthesized through chemoenzymatic synthesis (Li, Wolfert, et al. 2020). Another fundamental approach in glycobiology is structure elucidation. This is typically performed through a range of techniques, such as monomer analysis, MS and NMR (Reuel et al. 2012). Mass spectrometry analysis of glycans can require a lot of expertise. Improvements can be made in purification before measuring, mass labels and annotation of the data (Pilobello and Mahal 2007).

Summary

Bacteria are covered by glycans. In the cases described here, and possibly even more, bacteria display glycans that mimic glycans found in their human or animal host. This glycan mimicry is often found for gram-negative and mucosal pathogens. Bacterial glycans are important for many interactions that could possibly result in infection. For bacterial glycans mimicking their host, an increasing number of interaction partners have been identified, yet their effects beyond glycan recognition by host receptors are not always clear. In general, the overall function of glycan mimicry by bacteria remains to be studied. The techniques developed for chemical glycobiology could aid in identifying bacteria that display glycan mimicry and elucidate the function of glycan mimicry. Click here for additional data file.
  142 in total

1.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

2.  Identification of a sialate O-acetyltransferase from Campylobacter jejuni: demonstration of direct transfer to the C-9 position of terminalalpha-2, 8-linked sialic acid.

Authors:  R Scott Houliston; Hubert P Endtz; Nobuhiro Yuki; Jianjun Li; Harold C Jarrell; Michiaki Koga; Alex van Belkum; Marie-France Karwaski; Warren W Wakarchuk; Michel Gilbert
Journal:  J Biol Chem       Date:  2006-02-14       Impact factor: 5.157

Review 3.  Getting a grip on glycans: A current overview of the metabolic oligosaccharide engineering toolbox.

Authors:  Tjerk J Sminia; Han Zuilhof; Tom Wennekes
Journal:  Carbohydr Res       Date:  2016-09-16       Impact factor: 2.104

4.  Bacterial Cell Wall Modification with a Glycolipid Substrate.

Authors:  Phillip J Calabretta; Heather L Hodges; Matthew B Kraft; Victoria M Marando; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2019-06-04       Impact factor: 15.419

5.  Characterization of a transposon Tn916-generated mutant of Haemophilus ducreyi 35000 defective in lipooligosaccharide biosynthesis.

Authors:  B W Gibson; A A Campagnari; W Melaugh; N J Phillips; M A Apicella; S Grass; J Wang; K L Palmer; R S Munson
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

Review 6.  Advances in cell surface glycoengineering reveal biological function.

Authors:  Nicole Nischan; Jennifer J Kohler
Journal:  Glycobiology       Date:  2016-04-10       Impact factor: 4.313

7.  Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation.

Authors:  Ismael Secundino; Anel Lizcano; K Markus Roupé; Xiaoxia Wang; Jason N Cole; Joshua Olson; S Raza Ali; Samira Dahesh; Lenah K Amayreh; Anna Henningham; Ajit Varki; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2015-09-28       Impact factor: 4.599

8.  N-glycosylated proteins and distinct lipooligosaccharide glycoforms of Campylobacter jejuni target the human C-type lectin receptor MGL.

Authors:  Nina M van Sorge; Nancy M C Bleumink; Sandra J van Vliet; Eirikur Saeland; W-Ludo van der Pol; Yvette van Kooyk; Jos P M van Putten
Journal:  Cell Microbiol       Date:  2009-08-13       Impact factor: 3.715

Review 9.  Deciphering the glycocode: the complexity and analytical challenge of glycomics.

Authors:  Kanoelani T Pilobello; Lara K Mahal
Journal:  Curr Opin Chem Biol       Date:  2007-05-17       Impact factor: 8.822

10.  Can Campylobacter coli induce Guillain-Barré syndrome?

Authors:  A van Belkum; B Jacobs; E van Beek; R Louwen; W van Rijs; L Debruyne; M Gilbert; J Li; A Jansz; F Mégraud; H Endtz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.